HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Antiseptic Additional Identity Statement, Indications Requested By Gojo

This article was originally published in The Rose Sheet

Executive Summary

FDA should expand "statements of identity" under the OTC topical antimicrobial products tentative final monograph to allow products to be labeled as "hand sanitizers," according to Gojo Industries

You may also be interested in...



Skin Protectant Reduced Labeling For All Lip Products Urged By Mentholatum

The OTC skin protectant products final monograph should allow all lip protectants and lip balms the same leeway in labeling that is currently permitted for select lip products, the Mentholatum Company contends in recent comments to FDA

Skin Protectant Reduced Labeling For All Lip Products Urged By Mentholatum

The OTC skin protectant products final monograph should allow all lip protectants and lip balms the same leeway in labeling that is currently permitted for select lip products, the Mentholatum Company contends in recent comments to FDA

Triclocarban 1.5% Category I Antimicrobial Status Sought By P&G

FDA should include triclocarban at levels of up to 1.5% as a Category I ingredient in its OTC topical antimicrobial products final monograph, Procter & Gamble states in Aug. 19 comments to the agency

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel